-
公开(公告)号：US09738898B2
公开(公告)日：2017-08-22
申请号：US12867724
申请日：2009-02-13
Applicant: Susan L. Lindquist , Aaron D. Gitler
Inventor： Susan L. Lindquist , Aaron D. Gitler
CPC classification number: C12N15/81 , C12N15/1079 , G01N33/6872 , G01N33/6896 , G01N2500/10
Abstract: Disclosed are yeast cells expressing TAR DNA-binding protein 43 (TDP-43) and methods of screening yeast cells to identify compounds that prevent or suppress TDP-43-induced toxicity, compounds that inhibit the formation or maintenance of cytoplasmic inclusions of TDP-43, genetic suppressors or enhancers of TDP-43-induced toxicity, and genetic suppressors or enhancers of the formation or maintenance of cytoplasmic inclusions of TDP-43. Compounds identified by such screens can be used to treat or prevent TDP-43 proteinopathies such as frontotemporal lobar degeneration or amyotrophic lateral sclerosis.
-
公开(公告)号：US09677079B2
公开(公告)日：2017-06-13
申请号：US13521966
申请日：2011-01-11
Applicant: Kent E. S. Matlack , Susan L. Lindquist , Sebastian Treusch
Inventor： Kent E. S. Matlack , Susan L. Lindquist , Sebastian Treusch
CPC classification number: C12N15/81 , C07K14/4711
Abstract: Disclosed are yeast cells expressing a polypeptide comprising a signal sequence and a human amyloid beta protein. Also disclosed are methods of screening yeast cells to identify compounds that prevent or suppress amyloid beta-induced toxicity and genetic suppressors or enhancers of amyloid beta-induced toxicity. Compounds identified by such screens can be used to treat or prevent neurodegenerative disorders such as Alzheimer's disease.
-
3.发明授权Compounds, compositions and methods of inhibiting alpha-synuclein toxicity 有权抑制α-突触核蛋白毒性的化合物，组合物和方法公开(公告)号：US08440705B2
公开(公告)日：2013-05-14
申请号：US11575481
申请日：2005-09-16
Applicant: Susan L. Lindquist , Tiago Outeiro , Richard Labaudinière
Inventor： Susan L. Lindquist , Tiago Outeiro , Richard Labaudinière
IPC: C07D277/82 , A61K31/428
CPC classification number: A61K31/522
Abstract: Compounds and compositions are provided for treatment or amelioration of one or more symptoms of α-synuclein toxicity, α-synuclein mediated diseases or diseases in which α-synuclein fibrils are a symptom or cause of the disease. In one embodiment, the compounds for use in the compositions and methods are heteroaryl acylguanidines, heteroarylhydrazones, dihydropyridones, heteroaryl and aryl styryl ketones, and heteroarylpyrazoles.
Abstract translation: 提供化合物和组合物用于治疗或改善α-突触核蛋白毒性，α-突触核蛋白介导的疾病或其中α-突触核蛋白原纤维是该疾病的症状或原因的疾病的一种或多种症状。 在一个实施方案中，用于组合物和方法的化合物是杂芳基酰基胍胺，杂芳基腙，二氢吡啶酮，杂芳基和芳基苯乙烯基酮和杂芳基吡唑。
-
4.发明授权Methods of identifying agents that diminish cellular toxicity associated with an α-synuclein polypeptide of Parkinson's disease in yeast 有权识别在酵母中减少与帕金森病的α-突触核蛋白多肽相关的细胞毒性的试剂的方法公开(公告)号：US08133679B2
公开(公告)日：2012-03-13
申请号：US12272031
申请日：2008-11-17
Applicant: Paul J. Muchowski , Susan L. Lindquist , Tiago Outeiro
Inventor： Paul J. Muchowski , Susan L. Lindquist , Tiago Outeiro
CPC classification number: C12Q1/025 , C12N15/81 , C12Q1/02 , G01N33/6896 , G01N2500/04
Abstract: Methods of screening candidate agents to identify lead compounds for the development of therapeutic agents for the treatment of a neurodegenerative disease, such as Huntington's Disease and Parkinson's Disease and methods for identifying a mutation in, or changes in expression of, a gene associated with neurodegenerative disease, such as Huntington's Disease and Parkinson's Disease, are provided.
Abstract translation: 筛选候选试剂以鉴定铅化合物用于开发用于治疗神经变性疾病如亨廷顿病和帕金森病的治疗剂的方法和用于鉴定与神经变性疾病相关的基因的突变或表达变化的方法 ，如亨廷顿舞蹈病和帕金森病。
-
5.发明授权Methods of identifying agents that diminish cellular toxicity associated with an α-synuclein polypeptide of parkinson's disease in yeast 有权识别在酵母中减少与帕金森病的α-突触核蛋白多肽相关的细胞毒性的试剂的方法公开(公告)号：US08735072B2
公开(公告)日：2014-05-27
申请号：US13418848
申请日：2012-03-13
Applicant: Paul J. Muchowski , Susan L. Lindquist , Tiago Outeiro
Inventor： Paul J. Muchowski , Susan L. Lindquist , Tiago Outeiro
CPC classification number: C12Q1/025 , C12N15/81 , C12Q1/02 , G01N33/6896 , G01N2500/04
Abstract: Methods of screening candidate agents to identify lead compounds for the development of therapeutic agents for the treatment of a neurodegenerative disease, such as Huntington's Disease and Parkinson's Disease and methods for identifying a mutation in, or changes in expression of, a gene associated with neurodegenerative disease, such as Huntington's Disease and Parkinson's Disease, are provided.
Abstract translation: 筛选候选试剂以鉴定铅化合物用于开发用于治疗神经变性疾病如亨廷顿病和帕金森病的治疗剂的方法和用于鉴定与神经变性疾病相关的基因的突变或表达变化的方法 ，如亨廷顿舞蹈病和帕金森病。
-
Patent Agency Ranking
公开(公告)号：US20100273776A1
公开(公告)日：2010-10-28
申请号：US12294893
申请日：2007-03-29
Applicant: Susan L. Lindquist , Tiago Outeiro , Richard Labaudinière , James Fleming , Christine Ellen Bulawa , Charlotte Weigel , Feng Liang , Sandeep Gupta , Amy Ripka
Inventor： Susan L. Lindquist , Tiago Outeiro , Richard Labaudinière , James Fleming , Christine Ellen Bulawa , Charlotte Weigel , Feng Liang , Sandeep Gupta , Amy Ripka
IPC: A61K31/519 , A61K31/4045 , A61K31/416 , A61K31/454 , A61K31/445 , A61K31/435 , A61K31/55 , C07D487/04 , C07D209/14 , C07D231/56 , C07D471/04 , A61P43/00 , A61P25/16 , A61P25/28 , C12N5/07
CPC classification number: A61K31/4178 , A61K31/27 , A61K31/445 , A61K31/473 , A61K31/55 , A61K45/06 , A61K2300/00
Abstract: Compounds and compositions are provided for treatment or amelioration of one or more symptoms of α-synuclein toxicity, α-synuclein mediated diseases or diseases in which α-synuclein fibrils are a symptom or cause of the disease.
Abstract translation: 提供化合物和组合物用于治疗或改善α-突触核蛋白毒性，α-突触核蛋白介导的疾病或其中α-突触核蛋白原纤维是疾病的症状或原因的疾病的一种或多种症状。
-
7.发明申请METHODS OF IDENTIFYING LEAD COMPOUNDS THAT MODULATE TOXICITY OF NEUROTOXIC POLYPEPTIDES 有权识别神经毒性多肽的毒性的铅化合物的方法公开(公告)号：US20090068111A1
公开(公告)日：2009-03-12
申请号：US12272031
申请日：2008-11-17
Applicant: Paul J. Muchowski , Susan L. Lindquist , Tiago Outeiro
Inventor： Paul J. Muchowski , Susan L. Lindquist , Tiago Outeiro
CPC classification number: C12Q1/025 , C12N15/81 , C12Q1/02 , G01N33/6896 , G01N2500/04
Abstract: Methods of screening candidate agents to identify lead compounds for the development of therapeutic agents for the treatment of a neurodegenerative disease, such as Huntington's Disease and Parkinson's Disease and methods for identifying a mutation in, or changes in expression of, a gene associated with neurodegenerative disease, such as Huntington's Disease and Parkinson's Disease, are provided.
Abstract translation: 筛选候选试剂以鉴定铅化合物用于开发用于治疗神经变性疾病如亨廷顿病和帕金森病的治疗剂的方法和用于鉴定与神经变性疾病相关的基因的突变或表达变化的方法 ，如亨廷顿舞蹈病和帕金森病。
-
8.发明申请Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity 有权化合物，组合物和抑制α-突触核蛋白毒性的方法公开(公告)号：US20080261953A1
公开(公告)日：2008-10-23
申请号：US11575481
申请日：2005-09-16
Applicant: Susan L. Lindquist , Tiago Outeiro , Richard Labaudiniere
Inventor： Susan L. Lindquist , Tiago Outeiro , Richard Labaudiniere
IPC: C07D277/82 , C07D263/58 , A61K31/423 , A61K31/428 , A61K31/4439 , C07D417/02 , C07D413/02 , C07D413/14 , C07D417/14 , A61K31/4184 , C07D235/04 , C07D215/00 , A61K31/47 , A61K31/44 , A61K31/38 , A61K31/506 , A61K31/517 , A61K31/5355 , A61K31/435 , A61K31/55 , C07D221/00 , A61P25/28
CPC classification number: A61K31/522
Abstract: Compounds and compositions are provided for treatment or amelioration of one or more symptoms of α-synuclein toxicity, α-synuclein mediated diseases or diseases in which α-synuclein fibrils are a symptom or cause of the disease. In one embodiment, the compounds for use in the compositions and methods are heteroaryl acylguanidines, heteroarylhydrazones, dihy-dropyridones, heteroaryl and aryl styryl ketones, and heteroarylpyrazoles.
Abstract translation: 提供化合物和组合物用于治疗或改善α-突触核蛋白毒性，α-突触核蛋白介导的疾病或其中α-突触核蛋白原纤维是该疾病的症状或原因的疾病的一种或多种症状。 在一个实施方案中，用于组合物和方法的化合物是杂芳基酰基胍胺，杂芳基腙，二氢氯吡啶酮，杂芳基和芳基苯乙烯基酮以及杂芳基吡唑。
-
公开(公告)号：US09018003B2
公开(公告)日：2015-04-28
申请号：US11914167
申请日：2006-05-12
Applicant: Susan L. Lindquist , Aaron D. Gitler , Anil Cashikar
Inventor： Susan L. Lindquist , Aaron D. Gitler , Anil Cashikar
CPC classification number: C12N15/113 , A61K38/1709 , C12N15/1086 , G01N33/6896 , G01N2500/00 , G01N2800/2821 , G01N2800/2835
Abstract: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
Abstract translation: 公开了当在表达α-突触核蛋白的细胞中过表达时抑制或增强α-突触核蛋白介导的细胞毒性的基因。 调节这些基因表达或编码蛋白活性的化合物可用于抑制α-突触核蛋白介导的毒性，并用于治疗或预防突触核蛋白病如帕金森病。 还公开了鉴定α-突触核蛋白介导的毒性抑制剂的方法。
-
公开(公告)号：US08501465B2
公开(公告)日：2013-08-06
申请号：US12809859
申请日：2008-12-22
Applicant: Susan L. Lindquist , Aaron D. Gitler
Inventor： Susan L. Lindquist , Aaron D. Gitler
CPC classification number: C12Q1/025 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N33/68 , G01N2333/47 , G01N2500/10
Abstract: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.029 seconds)
